<DOC>
	<DOC>NCT00952445</DOC>
	<brief_summary>The purpose of the study is to determine if repeated daily doses of T0903131 (INT131) Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Clinical Diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to enrollment Fasting Plasma Glucose between 126 and 240 mg/dL HemoglobinA1c (HbA1c) between 6.8% and 10.0% Fasting Cpeptide &gt; 0.8 ng/mL Treatment with any pharmacotherapy for Type 2 Diabetes Mellitus within previous 6 weeks prior to screening Prior treatment with Thiazolidinedione, including Troglitazone, Rosiglitazone, pioglitazone BMI &gt; 42 kg/m2 Presence of any diabetic complications requiring chronic therapy Presence or history of any form of hepatic disease Serum creatinine &gt; 1.8 mg/dL History of cardiac arrhythmias or abnormal cardiac electrophysiology Any reason that, in the Investigator's judgment, would have interfered with the ability of the subject to comply with the requirements of the protocol</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>